THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
|
|
- Samson Patterson
- 5 years ago
- Views:
Transcription
1 James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention Director, Bellevue Hospital Lipid Clinic Past President, National Lipid Association New York, NY Jointly provided by and This activity is supported by educational funding provided by Amgen. Elevated LDL-C Cardiovascular Pathobiology
2 Support for LDL-C Causality in ASCVD Four compelling lines of evidence Experimental models Observational human data Genetic studies Interventional human trials ASCVD = atherosclerotic cardiovascular disease Substantial CVD Risk Remains after ACS 43,810 Patients with ACS in GRACE Registry: 6-month Death Rate 16 Death (%) STEMI NSTEMI UA Days GRACE = global registry of acute coronary events STEMI: ST-segment elevation MI NSTEMI: nonst-segment elevation MI UA: unstable angina Fox KAA et al. BMJ. 2006;333:1091.
3 Disease Trajectories and CVD Risk Reduction Packard CJ et al. Vasc Pharmacol. 2015;71: LDL-C Reduction Cardiovascular Benefits
4 Table 6. Risk-Enhancing Factors for Clinician Patient Risk Discussion Risk Enhancing Factors Family history of premature ASCVD (males, age <55 y; females, age <65 y) Primary hypercholesterolemia (LDL C, mg/dl [ mmol/l); non HDL C mg/dl [ mmol/l])* Metabolic syndrome (increased waist circumference, elevated triglycerides [>175 mg/dl], elevated blood pressure, elevated glucose, and low HDL C [<40 mg/dl in men; <50 in women mg/dl] are factors; tally of 3 makes the diagnosis) Chronic kidney disease (egfr ml/min/1.73 m 2 with or without albuminuria; not treated with dialysis or kidney transplantation) Chronic inflammatory conditions such as psoriasis, RA, or HIV/AIDS History of premature menopause (before age 40 y) and history of pregnancyassociated conditions that increase later ASCVD risk such as preeclampsia High risk race/ethnicities (e.g., South Asian ancestry) Table 6 (continued) Risk Enhancing Factors Lipid/biomarkers: Associated with increased ASCVD risk o Persistently* elevated, primary hypertriglyceridemia ( 175 mg/dl); o If measured: Elevated high sensitivity C reactive protein ( 2.0 mg/l) Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) 50 mg/dl or 125 nmol/l constitutes a risk enhancing factor especially at higher levels of Lp(a). Elevated apob 130 mg/dl: A relative indication for its measurement would be triglyceride 200 mg/dl. A level 130 mg/dl corresponds to an LDL C >160 mg/dl and constitutes a riskenhancing factor ABI <0.9
5 Treatments for Hypercholesterolemia Lifestyle Change Physical activity Medical nutrition therapy Smoking cessation Pharmacologic Therapy Statins Cholesterol absorption inhibitors Bile acid sequestrants Fibrates Omega-3 fish oil PCSK9 inhibitors MTP inhibitors Antisense apo B oligonucleotide Combination therapies Jellinger P et al. Endocr Practice. 2017;23: Statins The Gold Standard for LDL-C Reduction and ASCVD Prevention
6 Statins Protect against Recurrence in ASCVD Patients Secondary Prevention Statin Trials: CHD Event Rates -P=placebo; -AT=atorvastatin; -PR=pravastatin O Keefe JH et al. J Am Coll Cardiol. 2004;43: Lower On-treatment LDL-C with Statins Predicts Lower ASCVD Risk LDL-C Levels and Risk of CV Events LDL-C (mg/dl) < < < < <75 < Adjusted Hazard Ratio 95% Cl Boekholdt SM et al. J Am Coll Cardiol. 2014;64:
7 Elevated LDL Causes ASCVD LDL-C lowering Reduces ASCVD Cumulative LDL burden atheroprogression On-treatment LDL-C ASCVD Best evidence is for LDL receptors But likely not exclusive to this mechanism Early treatment to LDL-C is better than late treatment Lowest LDL-C is best Ference BA et al. Eur Heart J. 2017;38: Primary Prevention: Assess ASCVD Risk in Each Age Group Emphasize Adherence to Healthy Lifestyle Age 0-19 y Lifestyle to prevent or reduce ASCVD risk Diagnosis of Familial Hypercholesterolemia statin Age y Estimate lifetime risk to encourage lifestyle to reduce ASCVD risk Consider statin is family history premature ASCVD and LDL-C >160 mg/dl (>4.1 mmol/l0 Age y and LDL-C 70-<190 mg/dl ( 1.8-<4.9 mmol/l) without diabetes mellitus 10 year ASCVD risk percent begins risk discussion LDL-C 190 mg/dl (24.9 mmol/l) No risk assessment; High-Intensity statin (Class I) Diabetes mellitus and age y Moderate-Intensity statin (Class I) Diabetes mellitus and age y Risk assessment to consider high-intensity statin (Class IIa) Age >75 y Clinical assessment, Risk reduction
8 <5% Low Risk 5% - <7.5% Borderline Risk 7.5% - <20% Intermediate Risk 20% High Risk Risk discussion: Emphasize lifestyle to reduce risk factors (Class I) Risk discussion: If risk enhancers present then risk discussion regarding moderateintensity statin therapy (Class IIb) Risk discussion: If risk estimate + risk enhancers favor statin, initiate moderate-intensity statin to reduce LDL- C by 30% - 49% (Class I) Risk discussion: Initiate statin to reduce LDL-C 50% (Class I) If risk decision is uncertain: Consider measuring CAC in selected adults: CAC = zero (lowers risk; consider no statin, unless diabetes, family history of premature CHD, or cigarette smoking are present) CAC = 1.99 favors statin (especially after age 55) CAC = 100+ and/or 75th percentile, initiate statin therapy Secondary Prevention
9 Table 4. Very High-Risk* of Future ASCVD Events Major ASCVD Events Recent ACS (within the past 12 mo) History of MI (other than recent ACS event listed above) History of ischemic stroke Symptomatic peripheral arterial disease (history of claudication with ABI <0.85, or previous revascularization or amputation) Table 4 (continued) High-Risk Conditions Age 65 y Heterozygous familial hypercholesterolemia History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major ASCVD event(s) Diabetes mellitus Hypertension CKD (egfr ml/min/1.73 m 2 ) Current smoking Persistently elevated LDL-C (LDL-C 100 mg/dl [ 2.6 mmol/l]) despite maximally tolerated statin therapy and ezetimibe History of congestive HF
10 Intensive Statin Therapy Reduces MACE PROVE IT - TIMI 22: Study Design 4,162 patients with an Acute Coronary Syndrome <10 days Double-blind Standard Statin Therapy Pravastatin 40 mg ASA + Standard Medical Therapy 2x2 Factorial: Gatifloxacin vs placebo Intensive StatinTherapy Atorvastatin 80 mg Cannon CP et al. N Engl J Med. 2004;350: Duration: Mean 2 year follow-up (>925 events) Primary Endpoint: Death, MI, documented UA requiring hospitalization, revascularization (>30 days after randomization), or stroke Intensive Statin Therapy: PROVE IT-TIMI 22 All-Cause Death or Major CV Events % of Patients with MACE Intensive Statin Therapy Pravastatin 40mg (26.3%) Standard Statin Therapy Atorvastatin 80mg (22.4%) 16% RR (P=0.005) Cannon CP et al. N Engl J Med. 2004;350: Months of Follow-up
11 Intensity of Statin Therapies, Based on Clinical Trials High, Moderate, and Low-intensity High-intensity Statin Therapy Moderate-intensity Statin Therapy Low-intensity Statin Therapy Daily dose lowers LDL-C, on average, by approximately 50% Atorvastatin 40*-80* mg Rosuvastatin 20*-40** mg *Statins demonstrated reduction in major CVD events **FDA-approved doses not tested in clinical trials Daily dose lowers LDL-C, on average, by approximately 30% to <50% Atorvastatin 10* (20**) mg Rosuvastatin (5**) 10* mg Simvastatin 20*-40* mg Pravastatin 40* (80**) mg Lovastatin 40* mg Fluvastatin XL 80** mg Fluvastatin 40 mg BID* Pitavastatin 2-4** mg Daily dose lowers LDL-C, on average, by approximately <30% Simvastatin 10** mg Pravastatin 10*-20* mg Lovastatin 20* mg Fluvastatin 20**-40** mg Pitavastatin 1** mg Stone NJ et al. Circulation. 2014;129(25 Suppl 2):S1-45. Goff DC et al. Circulation. 2014;129(25 Suppl 2):S Add-on Therapies to Statins To Enhance LDL-C Reduction and Lower CVD Risk
12 Efficacy of Statin Treatment to Lower LDL-C Only about 1/3 of High-risk Patients Achieve LDL-C Goal All Patients High-Risk 1 o Prevention Secondary Prevention 71 Patients Achieving LDL-C Goal (%) Electronic Medical Records ( ) 0 High-Risk Patients CHD Patients At High-Risk 1 o Prev Goal (<100 mg/dl) At High-Risk LDL-C Goal (<70 mg/dl) CHD Patients At 2 o Prev at LDL-C Goal Goal (<100 mg/dl) (<70 mg/dl) Jones PH et al. J Am Heart Assoc. 2012;1:e Residual CHD Risk Despite Statin Monotherapy
13 Considerable ASCVD Risk Remains Despite Even Intensive Statin Monotherapy Statin-based LDL-C lowering to reduce CAD risk 2-10 Relative Risk Reduction (%) S CARE WOSCOPS LIPID AFCAPS HPS CARDS ASCOT 24% 24% 24% 29% 34% 37% 37% 36% R E S I D U A L R I S K JUPITER 44% Statins reduce CAD/CVD risk by ~24%-44% but 56% to 76% residual risk remains Adapted from Rader DJ et al Shepherd J et al. N Engl J Med. 1995;333: Scandinavian Simvastatin Survival Study Group. Lancet. 1994;344: Ballantyne CM. Am J Cardiol. 1998;82:3Q-12Q. 5. Sacks FM et al. N Engl J Med. 1996;335: Downs JR et al. JAMA. 1998;279: LIPID Study Group. N Engl J Med. 1998;339: Brown BG. Eur Heart J Suppl. 2005;7:F34-F Grundy SM et al. Circulation. 2004;110: Ridker PM et al. N Engl J Med. 2008;359: Non-statin Add-on LDL-lowering Therapies Ezetimibe
14 Ezetimibe: IMPROVE IT Trial Design Patients stabilized post-acs 10 days LDL-C 125 mg/dl (or 100 mg/dl if prior statin) Double-blind n ~ 18,000 ASA + Standard Medical Therapy Simvastatin 40 mg* Ezetimibe / Simvastatin 10/40 mg* *up-titrated to 80 mg if LDL-C >79 mg/dl Follow-up visit day 30, every 4 months Duration: Minimum 2.5 year follow-up (5250 events) Primary Endpoint: CV death, MI, Hospitalization for UA, Revascularization (>30 days after randomization), or Stroke Study drug is administered once daily in the evening. Cannon CP et al. Am Heart J. 2008;156: IMPROVE-IT Trial LDL-C and Other Lipid Effects with Ezetimibe 1 Yr Mean LDL-C TC TG HDL hscrp Simva EZ/Simva Δ in mg/dl Median Time avg 69.5 vs mg/dl Cannon CP et al. Am Heart J. 2008;156:
15 IMPROVE IT Trial: Ezetimibe + Simvastatin Lowers ASCVD More than Simvastatin Alone ~10% relative risk after 1 st year Primary endpoint: cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization Cannon CP et al. N Engl J Med. 2015;372: Non-statin Add-on LDL-lowering Therapies PCSK9 Inhibitors
16 Rationale Behind PSCK9 as a Therapeutic Target Rationale Behind PSCK9 as a Therapeutic Target PCSK9 # of LDL Receptors LDL-C PCSK9 # of LDL Receptors LDL-C
17 Physiology of PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 PCSK9 retains LDL-R in endosome LDL-R destruction LDL removal plasma LDL-C Sever P, Mackay J. Br J Cardiol. 2014;21: Giugliano RP et al. Lancet. 2012;380: Sabatine MS et al. N Engl J Med. 2015;372: PCSK9 Mutations and Effect on LDL Metabolism Gain of Function LDL-R levels LDL clearance Loss of Function LDL-R levels LDL clearance LDL High risk for ASCHD) LDL Protection from atherosclerosis and CHD LDL = low-density lipoprotein Adapted from Catapano AL, Papadopoulos N. Atherosclerosis. 2013;228: Soufi M et al. Gene. 2013;521:
18 PCSK9 Loss-of-Function Mutations Resulted in Lower LDL-C Levels and Reduced CHD Rates Wild-type PCSK9 degrades LDL receptors 1,2 1%-3% of population have a loss-offunction (LOF) mutation LOF mutations increase hepatic LDL receptor expression, reducing LDL-C levels by 15%-40% 2,3 CHD incidence was reduced 47%- 88% in PCSK9 loss-of-function mutation carriers compared with normal individuals 3 CHD (%) Black Subjects P= n=3,278 n=85 White Subjects 11.8 P= n=9,223 n=301 Normal Subject Mutation Carrier 1. Peterson AS et al. J Lipid Res. 2008;49: Cohen J et al. Nature Genetics. 2005;37: Cohen JC et al. N Engl J Med. 2006;354: PCSK9 Inhibition Enhanced LDL-C Reduction and Reduced CVD Risk
19 LDL-C Lowering Efficacy Dose-Response of Alirocumab and Evolocumab* ALIROCUMAB mab added to stable atorva dose of mg QD with LDL-C 100 mg/dl n=183, Duration = 12 wks % Change LDL-C EVOLOCUMAB mab added to stable statin and LDL-C > ~85 mg/dl n=631, Duration = 12 wks % Change LDL-C 50 mg Q2W -35% 70 mg Q2W -42% 100 mg Q2W -59% 105 mg Q2W -60% 150 mg Q2W -67% 140 mg Q2W -66% 300 mg Q4W -43% 280 mg Q4W -42% 350 mg Q4W -50% 420 mg Q4W -50% *Added to Stable Statin Therapy - Week 12 Giugliano et al. Lancet. 2012;380: McKenney et al. J Am Coll Cardiol. 2012;59: Clinical Outcomes of PCSK9 Inhibitors Meta-Analysis of 35 Randomized Clinical Trials End Point Fixed-effects Odds Ratio (95% CI) P Myocardial Infarction 0.72 ( ) <0.001 Stroke 0.8l ( ) 0.02 Coronary Revascularization 0.79 ( ) <0.001 All Cause Mortality* 1.00 ( ) Cardiovascular Mortality 1.01 ( ) Neurocognitive Adverse Events 1.12 ( ) *: A significant association was shown between LDL-C and benefit in all-cause mortality Karatasakis A et al. J Am Heart Assoc. 2017;6:e
20 Clinical Data on Alirocumab Alirocumab: ODYSSEY Outcomes Evaluation of Alirocumab After ACS Schwartz GG. Am Heart J. 2014;168:
21 ODYSSEY Outcomes Design: Alirocumab Dose Adjustments to Stay within LDL-C Target Range Undesirably high baseline range LDL-C (mg/dl) Schwartz GG et al. Am Heart J. 2014;168: e1. ODYSSEY Outcomes Design: Alirocumab Dose Adjustments to Stay within LDL-C Target Range We attempted to maximize the number of patients in the target range and minimize the number below target by blindly titrating alirocumab (75 or 150 mg SC Q2W) or blindly switching to placebo. 0 Below target Acceptable range Target range Alirocumab LDL-C (mg/dl) Undesirably high baseline range Approximately 75% of months of active treatment were at the 75 mg dose Schwartz GG et al. Am Heart J. 2014;168: e1. Steg G. Presented at: American College of Cardiology; March 2018.
22 ODYSSEY Outcomes: Alirocumab Lowers LDL-C Mean LDL-C (mg/dl) mg/dl 62.7% mg/dl 61.0% Placebo Alirocumab mg/dl % Months Since Randomization Excludes LDL-C values after premature treatment discontinuation or blinded switch to placebo Approximately 75% of months of active treatment were at the 75 mg dose Steg G. Presented at: American College of Cardiology; March Alirocumab: ODYSSEY Outcomes Alirocumab MACE by 15% ARR* 1.6% 4-Point MACE = CHD death, Non-fatal MI, Ischemic stroke Unstable angina requiring hospitalization Steg G. Presented at: American College of Cardiology; March *Based on cumulative incidence.
23 Alirocumab: ODYSSEY Outcomes Alirocumab MACE by 15%, same as Evolocumab ARR* 1.6% 4-Point MACE = 4-Point MACE = CHD CHD death, death, Non-fatal non-fatal MI, MI, Ischemic ischemic stroke Unstable unstable angina requiring hospitalization Steg G. Presented at: American College of Cardiology; March *Based on cumulative incidence. Alirocumab: ODYSSEY Outcomes Alirocumab Reduces MACE Steg G. Presented at: American College of Cardiology; March Late-Breaker Presentation.
24 Alirocumab Effects on Main Secondary Efficacy Endpoints: Hierarchical Testing in ODYSSEY Outcomes *Nominal P-value Steg G. Presented at: American College of Cardiology; March Late-Breaker Presentation. Alirocumab: ODYSSEY Outcomes Alirocumab May Reduce Total Mortality* *Nominal P-value Based on cumulative incidence ARR 0.6% Steg G. Presented at: American College of Cardiology; March Late-Breaker Presentation.
25 Alirocumab: ODYSSEY Outcomes Post Hoc Analysis: All-cause Death by Pre-specified Baseline LDL-C Subgroups Steg G. Presented at: American College of Cardiology; March Late-Breaker Presentation. Clinical Data on Evolocumab
26 Evolocumab: FOURIER LDL Cholesterol Sabatine MS et al. Am Heart J. 2016;173: Evolocumab: FOURIER Primary Efficacy Endpoint ARR 2.0% Sabatine MS et al. Am Heart J. 2016;173:
27 Evolocumab: FOURIER Key Secondary Endpoint Sabatine MS et al. Am Heart J. 2016;173: Evolocumab: FOURIER Landmark Analysis Sabatine MS et al. Am Heart J. 2016;173:
28 Lowest LDL-C is Best for ASCVD Prevention Evolocumab (FOURIER) Key 2 o Endpoint (CV Death, MI, or Stroke) LDL-C (mg/dl) Adj HR (95% CI) < ( ) ( ) ( ) ( ) > 100 referent P = Giugliano RP et al. Lancet. 2017;390: LDL-C 60 (mg/dl) 80 at 4 weeks Evolocumab Appears Effective (CVD) and Safe (SAE, D/C) to LDL-C <10 mg/dl* CARDIOVASCULAR EFFICACY 15 HR 0.69 ( ) P= mg/dl <10 mg/dl SAFETY HR 0.94 ( ) P= mg/dl <10 mg/dl Percent HR 0.59 ( ) P= Percent HR 1.08 ( ) P= CVD, MI, Stroke, UA, Cor Revasc CVD, MI, Stroke *Exploratory Analysis of FOURIER n = 504: Median [IQR] LDL-C: 7 [5-9] mg/dl Giugliano RP. Presented at: ESC Congress 2017, Barcelona; 8/28/ Serious adverse event AE -> drug discontinued An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School
29 Ebbinghaus: Evolocumab Evaluation of Cognition with Aggressive LDL-C Lowering CANTAB Tests Adj P trend Executive function 0.11 Working memory 0.61 Episodic memory 0.61 Reaction Time 0.47 Global Everyday Score Cognition Self Survey 0.30 Adj P trend Memory 0.11 Executive function 0.12 Planning 0.27 Organization 0.98 Divided attention Total Score Even slightly better scores at lower achieved LDL-C Giugliano RP et al. N Engl J Med. 2017;377: New Guidance for PCSK9 Inhibitors and Ezetimibe In Light of Cardiovascular Outcomes Data
30 Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) Recommendations for Primary Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) COR LOE Recommendations In patients 20 to 75 years of age with an LDL-C level of 190 I B-R mg/dl ( 4.9 mmol/l) or higher, maximally tolerated statin therapy is recommended. IIa B-R In patients 20 to 75 years of age with an LDL-C level of 190 mg/dl ( 4.9 mmol/l) or higher who achieve less than a 50% reduction in LDL-C while receiving maximally tolerated statin therapy and/or have an LDL-C level of 100 mg/dl ( 2.6 mmol/l) or higher, ezetimibe therapy is reasonable. Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) Recommendations for Primary Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) COR LOE Recommendations IIb B-R In patients 20 to 75 years of age with a baseline LDL-C level 190 mg/dl ( 4.9 mmol/l), who achieve less than a 50% reduction in LDL-C levels and have fasting triglycerides 300 mg/dl ( 3.4 mmol/l). while taking maximally tolerated statin and ezetimibe therapy, the addition of a bile acid sequestrant may be considered. IIb B-R In patients 30 to 75 years of age with heterozygous FH and with an LDL-C level of 100 mg/dl ( 2.6 mmol/l) or higher while taking maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered.
31 Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) Recommendations for Primary Severe Hypercholesterolemia (LDL-C 190 mg/dl [ 4.9 mmol/l]) COR LOE Recommendations IIb C-LD In patients 40 to 75 years of age with a baseline LDL-C level of 220 mg/dl ( 5.7 mmol/l) or higher and who achieve an on-treatment LDL-C level of 130 mg/dl ( 3.4 mmol/l) or higher while receiving maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. Value Statement: Uncertain Value (B-NR) Among patients with FH without evidence of clinical ASCVD taking maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors provide uncertain value at 2018 U.S. list prices. Approval/Reimbursement Barriers Faced by Patients % of Attempts to Get a PCSK9 Inhibitor Prescription that are Successful 100.0% 80.0% ASCVD (n=298) FH (n=284) Responses, % 60.0% 40.0% 64% of respondents with ASCVD patients and 57% of respondents with FH patients were unable to get 3 out of every 4 PCSK9 inhibitor prescriptions approved, despite multiple appeals 20.0% 0.0% Cohen JD et al. J Clin Lipidol. 2017;11: None 1-25% 26-50% 51-75% More Than 75% Successful approvals, %
32 Defining a Reimbursement Roadmap To Address Cumbersome Approval/Reimbursement Process More consistent criteria by payers and checklists, algorithms, apps, sharing of best practices which: Improve patient selection Help to assure that required documentation is submitted Reduce wasted time Avoid frustration by healthcare providers and patients in the approval/denial process Educational Resources from the National Lipid Association Visit the resource table in the foyer to pick up a copy of the NLA s Recommendations for Patient-Centered Management of Dyslipidemia, part I and part II, Pocket Guides. Want more? Visit Lipid.org to gain access to free online activities, educational flyers for your office, and more.
33 Thank you for joining us today! Please remember to complete the EVALUATION. Your participation will help shape future CME activities.
Educational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationHyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationPCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy
PCSK9 Inhibitors: Narnia vs. Medicare Bankruptcy Sergio Fazio, MD, PhD William and Sonja Connor Professor of Preventive Cardiology Professor of Medicine, Physiology & Pharmacology Director, Center for
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES
DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-249-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationManaging Lipids and Cardiovascular Risk: Using the Data to Optimize Care
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Faculty Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationControlling Cholesterol and Diet Modifications
Reducing your Risk of Heart Disease Webinar Series Controlling Cholesterol and Diet Modifications Created with an educational grant from: About Mended Hearts Mended Hearts mission is: To inspire hope and
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More information